PA8513601A1 - Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa - Google Patents

Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa

Info

Publication number
PA8513601A1
PA8513601A1 PA20018513601A PA8513601A PA8513601A1 PA 8513601 A1 PA8513601 A1 PA 8513601A1 PA 20018513601 A PA20018513601 A PA 20018513601A PA 8513601 A PA8513601 A PA 8513601A PA 8513601 A1 PA8513601 A1 PA 8513601A1
Authority
PA
Panama
Prior art keywords
glucogenophosphorilase
pharmaceutical compositions
inhibitors
inhibitor
polymer
Prior art date
Application number
PA20018513601A
Other languages
English (en)
Inventor
Douglas Alan Lorenz
Dennis Jay Hoover
Dwayne Thomas Friesen
Nightingale James Alan Schriver
Ravi Mysore Shanker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8513601A1 publication Critical patent/PA8513601A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

COMPOSICIONES FARMACEUTICAS QUE CONTIENEN UN INHIBIDOR DE LA GLUCOGENOFOSFORILASA Y COMO MINIMO UN POLIMERO QUE AUMENTA LA CONCENTRACION. LA COMPOSICION PUEDE SER UNA MEZCLA FISICA SIMPLE DE UN INHIBIDOR DE LA GLUCOGENO-FOSFORILASA Y UN POLIMERO QUE AUMENTA LA CONCENTRACION, O UNA DISPERSION DE UN INHIBIDOR DE LA GLUCOGENO-FOSFORILASA Y UN POLIMERO.
PA20018513601A 2000-03-16 2001-03-16 Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa PA8513601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16

Publications (1)

Publication Number Publication Date
PA8513601A1 true PA8513601A1 (es) 2004-08-31

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018513601A PA8513601A1 (es) 2000-03-16 2001-03-16 Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa

Country Status (32)

Country Link
US (1) US20010053778A1 (es)
EP (1) EP1263414A1 (es)
JP (1) JP2003526654A (es)
KR (1) KR20020081445A (es)
CN (1) CN1418089A (es)
AP (1) AP2002002621A0 (es)
AR (1) AR027656A1 (es)
AU (1) AU2001242669A1 (es)
BG (1) BG107037A (es)
BR (1) BR0109189A (es)
CA (1) CA2403241A1 (es)
CO (1) CO5280087A1 (es)
CZ (1) CZ20022955A3 (es)
EA (1) EA200200858A1 (es)
EE (1) EE200200530A (es)
HU (1) HUP0204583A2 (es)
IL (1) IL151320A0 (es)
IS (1) IS6508A (es)
MA (1) MA26882A1 (es)
MX (1) MXPA02009097A (es)
NO (1) NO20024386L (es)
OA (1) OA12232A (es)
PA (1) PA8513601A1 (es)
PE (1) PE20011184A1 (es)
PL (1) PL360780A1 (es)
SK (1) SK12622002A3 (es)
SV (1) SV2002000343A (es)
TN (1) TNSN01040A1 (es)
TR (1) TR200202184T2 (es)
WO (1) WO2001068055A1 (es)
YU (1) YU67202A (es)
ZA (1) ZA200207290B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0204372A3 (en) * 1999-12-23 2004-06-28 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
ATE486586T1 (de) * 2001-06-22 2010-11-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
WO2003000235A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
MXPA03011935A (es) * 2001-06-22 2004-03-26 Pfizer Prod Inc Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco.
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
JP2005523262A (ja) 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物
MXPA04007433A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
MXPA06001417A (es) 2003-08-04 2006-05-15 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas.
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
BRPI0418330A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas de drogas de solubilidade baixa e poloxámeros
US7884112B2 (en) 2004-03-08 2011-02-08 Stuart Edward Bradley Pyrrolopyridine-2-carboxylic acid hydrazides
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
CN107602710A (zh) 2012-08-24 2018-01-19 陶氏环球技术有限责任公司 新的具有高分子量和均匀性的酯化纤维素醚
EA201991484A1 (ru) 2012-09-11 2019-11-29 Лекарственные формы энзалутамида
AU2014290333B2 (en) * 2013-07-19 2018-11-08 Siga Technologies, Inc. Amorphous Tecovirimat preparation
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
PT832066E (pt) * 1995-06-06 2001-12-28 Pfizer N-substituido-(indole-2-carbonil)-amidas e derivados como inibidores de glicogenio-fosforilase
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
CN1418089A (zh) 2003-05-14
BR0109189A (pt) 2003-05-27
AR027656A1 (es) 2003-04-09
IL151320A0 (en) 2003-04-10
IS6508A (is) 2002-08-16
SV2002000343A (es) 2002-07-03
YU67202A (sh) 2006-01-16
OA12232A (en) 2006-05-10
EA200200858A1 (ru) 2003-02-27
TNSN01040A1 (fr) 2005-11-10
AP2002002621A0 (en) 2002-09-30
HUP0204583A2 (hu) 2003-04-28
WO2001068055A1 (en) 2001-09-20
CO5280087A1 (es) 2003-05-30
CA2403241A1 (en) 2001-09-20
MXPA02009097A (es) 2003-03-12
NO20024386L (no) 2002-11-13
PL360780A1 (en) 2004-09-20
JP2003526654A (ja) 2003-09-09
US20010053778A1 (en) 2001-12-20
BG107037A (bg) 2003-04-30
TR200202184T2 (tr) 2003-01-21
SK12622002A3 (sk) 2004-02-03
NO20024386D0 (no) 2002-09-13
ZA200207290B (en) 2003-09-11
EE200200530A (et) 2004-04-15
CZ20022955A3 (cs) 2003-09-17
EP1263414A1 (en) 2002-12-11
PE20011184A1 (es) 2001-11-15
MA26882A1 (fr) 2004-12-20
AU2001242669A1 (en) 2001-09-24
KR20020081445A (ko) 2002-10-26

Similar Documents

Publication Publication Date Title
PA8513601A1 (es) Composiciones farmaceuticas de inhibidores de la glucogenofosforilasa
UY26864A1 (es) Composiciones farmaceúticas de inhibidores de la proteína de transferencia de colesteril éster
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
UY27346A1 (es) Composiciones farmaccuticas que contienen conjuntos de polemero y frrmaco.
CY1105286T1 (el) Ω-καρβοξυαρυλυποκατεστημενες διφαινυλουριες σαν αναστολεις της raf κινασης
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
PT1117440E (pt) Composicoes farmaceuticas que contem paclitaxel
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
AR038207A1 (es) Composicion farmaceutica dispersable oralmente de agomelatina
TR200100054T2 (tr) Paroksetin metansülfonat
TR200200606T2 (tr) Lipaz inhibitörleri içeren dispersiyon terkipleri.
AU2003293555A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
AU2001275346A1 (en) Compositions, kits, and methods for identification and modulation of type i diabetes
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT
UY27610A1 (es) Combinación de inhibidores de ptm o inhibidores de la secreción de apob con fibratos para la utilización como medicamentos
DE602005010203D1 (de) Pharmazeutische zusammensetzung enthaltend 2,4-dichlorbenzylalkohol und amylmetakresol
AR030853A1 (es) Composicion plaguicida
AR046853A1 (es) Mezclas insecticidas que contienen triflumuron con actividad sinergica
SE0302361D0 (sv) Inhibering av upptagning av monoamin
UY26218A1 (es) Combinacion de inhibidores de mtp e inhibidores de hmg- coa reductasa y su uso en medicamentos. ley 17.164.-
ATE392644T1 (de) Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen
DE60041198D1 (de) Antimikrobielle zusammensetzungen